Ocean Biomedical Inc (OCEA) Actualités

Form PRE 14A - Other preliminary proxy statements

Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges

Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Ocean Biomedical, Inc. Joins the Russell 2000® Index

Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.

Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new...

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

  PROSPECTUS   Filed pursuant to Rule 424(b)(3) Registration Number 333-271392     OCEAN BIOM...

Securities Registration Statement (s-1)

0001869974 false

Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe

Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:June 22, 2023 4:30...

Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing

Providence, RI, June 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: “OCEA”), a next-generation...

Securities Registration Statement (s-1/a)

0001869974 true S-1/A

Small Company Offering and Sale of Securities Without Registration (d)

 UNITED STATES SECURITIESAND EXCHANGE COMMISSIONWashington, D.C.FORM DOMB APPROVALOMB Number: 3235-0076Estimated Average burden hours per...

Current Report Filing (8-k)

0001869974 false 0001869974 2023-06-08 2023-06-08 0001869974...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis

Patent for breakthrough approach to disrupting the malaria parasite’s life cycle adds to a growing global...